Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Reality Therapy
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by TheTruth1234on Nov 17, 2023 2:08pm
114 Views
Post# 35741594

RE:RE:RE:RE:RE:Some Reality Therapy

RE:RE:RE:RE:RE:Some Reality Therapy
InitiumMMXXIII wrote: No, no, I get it. Nobody reads my posts. Give a second, here. I have to take a second to roll my eyes.

I'm sticking around for a very simple reason. Bioasis has failed, it appears, and it outwardly appears to purely because of management failures. The only other explanation is that xB3 failed long ago. And yet, Bioasis has always stated that xB3 works as hoped, that there are no problems with it. I'm going to stay here and post until the question is resolved. If the company lied then I want to pursue that with every bit of knowledge and effort I can summon. If it was all about incompetence, then so be it. But if we were lied to...

About me being smarter or more informed than anybody else, you shouldn't be so intimidated by me, TT. You won't even try to keep up with me, evidenced by the very obvious and documented fact that you can't post about anything but me. Nothing about Bioasis, xB3, management or the market. Nothing. Zip.

You don't intimidate me in the least, TT. I'l post whenever and whatever I want.

You have the last word, TT, and I don't care what it is. Carry on, bud. Fill yer boots.

Bye bye for now...




If the company lied then I want to pursue that with every bit of knowledge and effort I can summon


But you want to get "paid"  for pursuing it though, right Johnny boy?

And by being bankrupt,  I highly doubt you can "pursue " with alot of effort!!


LMFAO!!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities